Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | PPARD | Q03181 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nectandrin B SCHEMBL29351645 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Tetrahydrofuroguaiacin B SCHEMBL29484565 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin B SCHEMBL30678749 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin B SCHEMBL13506165 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin B SCHEMBL12118675 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin B SCHEMBL893163 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Tetrahydrofuroguaiacin B SCHEMBL12118597 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin B SCHEMBL17145939 | 1.00 | NR3C1 (1.00) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin A SCHEMBL13506024 | 0.95 | NR3C1 (0.91) | NR3C1PTAFRCA2ALOX5PTPN1 | |
| Nectandrin A SCHEMBL893331 | 0.95 | NR3C1 (0.91) | NR3C1PTAFRCA2ALOX5PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144164-A1 | COMPOSITIONS, METHODS, AND MEDICAL COMPOSITIONS FOR TREATMENT OF AND MAINTAINING THE HEALTH OF THE LIVER | UNIGEN, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-10596212-B2 | Mangifera indica as a Sirtuin 1 activating agent | VITAL SOLUTIONS SWISS AG (CH) | 2020-03-24 | — | — | US | claimed |
| US-20190054096-A1 | METHODS FOR ATTENUATING PARASITE VIRULENCE | INST DE MEDICINA MOLECULAR (PT) | 2019-02-21 | — | — | US | claimed |
| CN-108472502-A | Compositions, methods and pharmaceutical compositions for treating and maintaining liver health | 尤尼根公司 | 2018-08-31 | — | — | CN | claimed |
| EP-3355876-A2 | METHODS FOR ATTENUATING PARASITE VIRULENCE | Instituto de Medicina Molecular (PT) | 2018-08-08 | — | — | EP | claimed |
| EP-2953485-B1 | MANGIFERA INDICA AS A SIRTUIN 1 ACTIVATING AGENT | VITAL SOLUTIONS SWISS AG (CH) | 2017-12-20 | — | — | EP | claimed |
| US-20170042957-A1 | MANGIFERA INDICA AS A SIRTUIN 1 ACTIVATING AGENT | BUCHWALD-WERNER, SYBILLE, DR. (DE) | 2017-02-16 | — | — | US | claimed |
| US-20170035829-A1 | Compositions, Methods, and Medical Compositions for Treatment of and Maintaining the Health of the Liver | UNIGEN, INC. (US) | 2017-02-09 | — | — | US | claimed |
| WO-2017011523-A1 | COMPOSITIONS, METHODS, AND MEDICAL COMPOSITIONS FOR TREATMENT OF AND MAINTAINING THE HEALTH OF THE LIVER | UNIGEN, INC. (US) | 2017-01-19 | — | — | WO | claimed |
| EP-2953485-A1 | MANGIFERA INDICA AS A SIRTUIN 1 ACTIVATING AGENT | Vital Solutions Swiss AG (CH) | 2015-12-16 | — | — | EP | claimed |
| WO-2015158836-A1 | MANGIFERA INDICA AS A SIRTUIN 1 ACTIVATING AGENT | VITAL SOLUTIONS SWISS AG (CH) | 2015-10-22 | — | — | WO | claimed |
| EP-2438923-B1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | UNIV CHOSUN IACF (KR) | 2015-03-18 | — | — | EP | claimed |
| CN-103936698-A | Composition For Preventing Or Treating Adiposity Or Metabolism Syndrome | UNIV CHOSUN IACF (KR) | 2014-07-23 | — | — | CN | claimed |
| CN-102481325-B | Composition for preventing or treating obesity-related diseases mediated by activation of AMPK, containing 2, 5-diaryl-3, 4-dimethyltetrahydrofurfuryl lignan as an active ingredient | UNIV CHOSUN IACF (KR) | 2014-05-28 | — | — | CN | claimed |
| US-20120083525-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | AMOREPACIFIC CORPORATION | 2012-04-05 | — | — | US | claimed |
| WO-2008096998-A1 | USE OF A SEEDS EXTRACT OF MYRISTICA FRAGRANS OR ACTIVE COMPOUNDS ISOLATED THEREFROM FOR PREVENTING OR TREATING OSTEOPOROSIS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-08-14 | — | — | WO | claimed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | claimed |
| US-20250144164-A1 | COMPOSITIONS, METHODS, AND MEDICAL COMPOSITIONS FOR TREATMENT OF AND MAINTAINING THE HEALTH OF THE LIVER | UNIGEN, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2007009201-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2007-01-25 | — | — | WO | disclosed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083525-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | PRKAG1, PRKAG3, PRKAG2 | NR3C1 3543/4885PTAFR 1160/4885CA2 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.